Statins were discloseed for their ...

Statins were discloseed for their antilipid properties, on the contrary they also act as anti-inflammatories. In vitro studies indicate that statins may be beneficial in treating rheumatoid arthritis. McCarey and colleagues studied the clinical weights of atorvastatin on patients with rheumatoid arthritis in a double-blind, random-ized, placebo-controlled trial.

united hundred and sixteen adults with continued active rheumatoid arthritis after at least three month of adequate disease-modifying antirheumatic put drugs into therapy participated in the studious mood Active disease was defined as at least six swollen joints and at least couple other features (six tender joints, 30 minutes or more of morning stiffness, or erythrocyte sedimentation rate [ESR] of 28 mm by hour or higher). Exclusion criteria included diabetes, elevated coronary heart disease risk, familial hypercholesterolemia, steroid intake of 10 mg or more by means of day, and significant renal insufficiency. Patients remained forward all therapy for rheumatoid arthritis and other conditions from head to foot the study. After assessment, patients were randomized to receive 40 mg of atorvastatin or placebo. The primary issue was change in the DAS28 scale, a validated composite disease activity score that incorporates ESR visual analog score for pain, and number of swollen or feminine joints. Additional outcomes included health assessment questionnaires, C-reactive protein, plasma lipids, and endothelial function markers. Physicians assessed patients after three and six month of therapy; evaluation included screening for changes in liver and kidney function.

The pair groups were generally comparable forward entry to the study, on the other hand pain scores and global assessments were slightly lower in the atorvastatin arrange At six months, DAS28 was significantly reduc in the atorvastatin assign places to compared with placebo. Thirty-one percent of the atorvastatin collection achieved moderate or good DAS28 answer com-pared with only 10 percent of the placebo form into groups The atorvastatin group also showed significant improvements in acute-phase reactants. horizontals of C-reactive protein and ESR declined by way of 50 and 28 percent respectively in patients receiving atorvastatin compared with those receiving placebo. These ensues remained consistant after adjusting for all significant variables. Other indicators of disease activity, particularly the number of swollen joints, also improved during atorvastatin therapy. remarkably few adverse events occurred in either cluster More atorvastatin patients completed the application of mind than placebo patients (53 not at home of 58 compared with 45 public of 58, respectively). More placebo patients received intramuscular or intra- articular steriod injections during the study

The authors decide that atorvastatin was associated with a modestly beneficial if it be not that clinically useful effect in patients with rheumatoid arthritis. They speculate that statins provide vascular protective and adjunctive immune- modifying general intents to disease-modifying antirheumatic drug therapy and could be effective in treating chronic inflammatory diseases.

McCarey DW et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-con-trolled trial. Lancet June 19 2004;363:2015-21

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group